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Deregulation of transcriptional networks contributes to haematopoietic malignancies. The transcription factor Spi-1/PU.1 is a master regulator of haematopoiesis and its alteration leads to leukaemia. Spi-1 overexpression inhibits differentiation and promotes resistance to apoptosis in erythroleukaemia. Here, we show that Spi-1 inhibits mitochondrial apoptosis in vitro and in vivo through the transcriptional repression of Bim, a proapoptotic factor. BIM interacts with MCL-1 that behaves as a major player in the survival of the preleukaemic cells. The repression of BIM expression reduces the amount of BIM-MCL-1 complexes, thus increasing the fraction of potentially active antiapoptotic MCL-1. We then demonstrate that Spi-1 represses Bim transcription by binding to the Bim promoter and by promoting the trimethylation of histone 3 on lysine 27 (H3K27me3, a repressive histone mark) on the Bim promoter. The PRC2 repressive complex of Polycomb is directly responsible for the deposit of H3K27me3 mark at the Bim promoter. SUZ12 and the histone methyltransferase EZH2, two PRC2 subunits bind to the Bim promoter at the same location than H3K27me3, distinct of the Spi-1 DNA binding site. As Spi-1 interacts with SUZ12 and EZH2, these results indicate that Spi-1 modulates the activity of PRC2 without directly recruiting the complex to the site of its activity on the chromatin. Our results identify a new mechanism whereby Spi-1 represses transcription and provide mechanistic insights on the antiapoptotic function of a transcription factor mediated by the epigenetic control of gene expression. Acute myeloid leukaemia (AML) develops through a multistep process driven by the progressive accumulation of mutations, leading to deregulation of cell proliferation and differentiation. Most frequently, abnormalities in cell differentiation are the result of loss-of-function mutations in lineage-specific transcription factors, whereas alterations in cell proliferation are associated with gain-of-function mutations in signalling pathways. 1 Mutations that target components of the spliceosomal machinery 2 and epigenetic regulators 3 have been identified as well, although their functional consequences in leukaemogenesis are not clear. To date, AML treatments are largely determined by the nature of the identified mutated proteins and a major challenge is to design molecules that can target each molecular alteration contributing to transformation. For that, understanding the molecular mechanisms controlled by an oncoprotein is one essential step. We have previously described a mouse model of erythroleukaemia (Spi-1 transgenic mice) that recapitulates the multistep development of human AML. 4 Spi-1 is a master transcription factor of haematopoiesis that is also involved in pre-mRNA splicing regulation. 5 During the preleukaemic stage of the disease, the differentiation blockage of the erythroid progenitors is the first oncogenic mark associated with Spi-1 activity. 6 Spi-1 is also responsible for resistance to apoptosis, acceleration of replication and increased genetic instability. 7, 8 The leukaemic stage of the disease is characterized by the emergence of malignant cells that have acquired Kit mutations promoting constitutive activation of signalling pathways. 4, 9 Apoptosis is a major defence in response to the loss of growth control, and many cancer cells develop antiapoptotic activities. 10 BCL-2 family members are major regulators of the commitment to programmed cell death and have pro-or antiapoptotic activities. 11, 12 The balance between proand antiapoptotic molecules is disrupted in many leukaemic cells, conferring resistance to apoptosis. Consequently, proteins of the BCL-2 family appear to be suitable targets for therapies in cancer. 13 To this end, it is crucial to identify the molecules that regulate the apoptotic machinery as well as their downstream effectors.
Here, we explored how Spi-1 induces resistance to apoptosis in the preleukaemic erythroid progenitors of the Spi-1 transgenic mice. We found that Spi-1 inhibits mitochondrial apoptosis both in vitro and in vivo through transcriptional repression of Bim. We then demonstrate that interaction of Spi-1 with the polycomb repressive complex 2 (PRC2) promotes epigenetic modifications that have a major role in repressing Bim transcription. Our results argue for a new mechanism of transcriptional repression by Spi-1 that involves the modification of PRC2 activity to create a repressive chromatin context in the preleukaemic cells.
Results
Spi-1 inhibits mitochondrial apoptosis. Here, we investigated whether Spi-1 protects preleukaemic cells from apoptosis by influencing the apoptotic mitochondrial pathway. We used preleukaemic Spi-1 transgenic cell lines previously established with a doxycycline (dox)-inducible shRNA against Spi-1 (shSpi-1-A2B and shSpi-1-A2C cells). 8 The percentage of cells with reduced mitochondrial membrane potential (DF) (Figure 1a) , of dead cells (Figure 1b ) and of cells that expressed cleaved-caspase-3 (the active form) (Figure 1c) , was increased when Spi-1 was silenced. Upon activation, BAX undergoes a conformational change detectable using the anti-BAX monoclonal antibody 6A7. 14, 15 Immunoprecipitation (IP) experiments showed that Spi-1 downregulation by dox treatment induced the exposure of the 6A7 epitope ( Figure 1d ). Altogether, these results indicate that Spi-1 inhibits the mitochondrial apoptotic pathway.
Spi-1 decreases BIM expression in preleukaemic cells.
Mitochondrial apoptosis is regulated through the balance between pro-and antiapoptotic BCL-2 family members. Transcriptomic data we previously obtained 16 indicated that the proapoptotic Bmf, Hrk and Noxa and the antiapoptotic Bcl2 and A1 genes were not expressed in shSpi cells cultured with or without dox (see Supplementary Figure 1A and Ridinger-Saison et al. 16 ). Therefore, we evaluated the protein level of the other BCL-2 family members in two independent shSpi cell lines (shSpi-1-A2B and shSpi-1-A2C) and control cells cultured with or without dox for 2 days.
Among the antiapoptotic factors, BCL-X L expression was slightly decreased in cells treated with dox (x0.75), whereas the protein level of MCL-1 and BCL-W was not changed (Figure 2a ). Among the proapoptotic factors, the expression of PUMA, BAX and BAK was not modified by dox treatment (Figure 2b) . The BAD protein level and phosphorylation (Figures 2b and c) were slightly higher in cells grown with dox (x1.5) than in cells cultured without dox. As phosphorylated BAD is inactive, 17 the increase in its phosphorylation should not be related to the apoptosis induced by Spi-1 knockdown. BID and its activated form tBID were slightly increased in cells treated with dox compared with untreated cells. This increase appears poorly relevant when compared with that induced by staurosporine (STS), which was used as an apoptosis inducer (Figure 2d ). The most prominent effect associated with Spi-1 silencing in preleukaemic cells concerned BIM expression. BIM is a proapoptotic factor with three major isoforms (short, BIM S ; long, BIM L ; and extra-long, BIM EL ). 18 In preleukaemic cells, BIM EL was the most abundant isoform, whereas BIM L expression was modest and BIM S was barely detectable. The addition of dox strongly increased BIM EL and BIM L protein levels in the two shSpi cell lines (3-4 times) (Figure 2b ), suggesting that the antiapoptotic effect of Spi-1 may result from its ability to maintain BIM expression low.
Spi-1 exerts its antiapoptotic function through repression of BIM expression. To assess whether low BIM expression is required for Spi-1 antiapoptotic function, we transfected a HA-tagged Bim expression vector in the preleukaemic cells (Figure 3a ). An increase (twofold) in the percentage of dead and apoptotic cells was detected (Figure 3b ), indicating that BIM overexpression is sufficient to trigger apoptosis in preleukaemic cells. To determine whether increased BIM expression is required for apoptosis induced by Spi-1 knockdown, we introduced shRNA against Bim (shBim) or scrambled shRNA (shSbl) in the preleukaemic cells and cultured them with or without dox. The shBim expression reduced by 50% the upregulation of Bim associated with Spi-1 knock-down (Figure 3c ). This results in a decrease in the percentage of dead cells (Figure 3d ) and of cells that expressed active caspase-3 (Figures 3c and d) .
Thus, Bim silencing significantly overcame apoptosis induced by Spi-1 knockdown. These results demonstrate that the antiapoptotic function of Spi-1 in preleukaemic cells requires low BIM expression.
Spi-1 inhibits Bim expression and protects preleukaemic cells from apoptosis also in vivo. Then, we investigated whether resistance to apoptosis and low BIM expression were also observed in primary preleukaemic cells isolated from Spi-1 transgenic mice. 6 As Spi-1 induces resistance to apoptosis in erythroid progenitors, we used flow cytometry to purify such cells. Specifically, the earliest erythropoietin (EPO)-dependent progenitors (the colonyforming unit-erythroid, CFU-E) are CD71 À cells (around 30 and 55 versus 10% and 1%, respectively) that were mainly IL3Ra À (around 80%). Only CD71 high Ter119 À IL3Ra À cells required EPO to expand in methylcellulose, leading to consider them as preleukaemic blasts.
We compared apoptosis in CD71 high Ter119 À IL3Ra À cells from wt and Spi-1 transgenic leukaemic mice. The percentage of Annexin V-positive apoptotic cells from preleukaemic mice (11%) was lower than in wt mice (22%) (Figure 4c ). No significant difference in the number of Annexin V-positive apoptotic CD71
À Ter119 À non-erythroid cells was observed in wt and preleukaemic mice. In parallel, we found that Spi-1 expression was higher (sevenfold, Po0.001) in CD71 high Ter119 À IL3Ra À cells from Spi-1 transgenic preleukaemic mice than in wt animals ( Figure 4d ). Conversely, À IL3Ra À (left) and CD71 À Ter119 À (right) cells from wt and Spi-1 Tg mice were quantified by real-time qPCR and normalized to the Polr2a mRNA level (Ctgene-Ctpolr2a). Bars correspond to the mean DCt±S.D. of at least three independent experiments. Statistical analysis of the DCt values was carried out by using the Student's t-test; ***Po0.001 and *Po0.05. For easier interpretation, we added on the right the histograms representing the fold change relative to wt mice, calculated from the 2 À Ter119 À non-erythroid cells of wt and preleukaemic mice. These results validate the relationship between the high expression of Spi-1, the weak expression of BIM and the resistance to apoptosis in primary preleukaemic cells.
MCL-1 contributes to the survival of preleukaemic cells. BIM could carry out its proapoptotic function by interacting with the antiapoptotic factors BCL-X L or MCL-1 that are expressed in the preleukaemic cells, thereby acting as an antagonist of these proteins. [22] [23] [24] [25] [26] We investigated whether MCL-1 and BCL-X L interacted with BIM by co-IP. MCL-1, but not BCL-X L , was detected in BIM immunoprecipitates (Figure 5a ). Moreover, in dox-treated cells (Spi-1 knocked down) the amount of MCL-1 complexed with BIM was clearly increased. As MCL-1 expression was not influenced by Spi-1 knockdown (Figure 2 ), the increased amount of BIM-MCL-1 complexes strongly suggests that the pool of free, active MCL-1 is reduced upon Spi-1 silencing. Consequently, BIM proapoptotic effect may, at least in part, occur through neutralization of the antiapoptotic MCL-1. These results prompted us to quantify the effect of MCL-1 silencing on survival of preleukaemic cells using Mcl-1-shRNA. The reduction of MCL-1 expression (80% of decrease) increased the number of dead cells (twofold) and of cells that expressed cleaved-caspase 3 (threefold) in comparison with shSbl cells (Figure 5b) . Thus, MCL-1 contributes decisively to the survival of preleukaemic cells.
Altogether, our data suggest that Spi-1 promotes resistance to apoptosis in preleukaemic cells by inhibiting the expression of BIM. This in turn leads to an increase of the free pool of MCL-1 that can protect cells from apoptosis.
Downregulation of Bim in preleukaemic cells is due to transcriptional repression by Spi-1. We aimed to determine the mechanism of BIM downregulation associated with Spi-1 expression. Bim transcript and protein expression was induced as soon as 26 h after dox treatment ( Supplementary Figures 2A and B) , showing that the regulation of Bim expression occurs first at the transcriptional level. As Bim mRNA can be stabilized through binding of the heat-shock cognate 70 to the Bim 3 0 -UTR, 27 we (Figure 6a) . Thus, the inhibition of Bim expression by Spi-1 occurs at the level of the initiation of transcription.
Spi-1 binds to the Bim promoter and promotes H3K27 trimethylation, a repressive histone mark. To further investigate how Spi-1 restrains the Bim transcription, we screened transcription factor binding sites on the Bim promoter using the Genomatix-MatInspector module. We found one putative Spi-1 binding site located 0.3 kb upstream of the Bim transcriptional start site (TSS). To determine the biological relevance of this Spi-1 binding site, we performed chromatin IP (ChIP) experiments using an anti-Spi-1 antibody in shSpi-1-A2C and shSpi-1-A2B cells. The Bim promoter region was immunoprecipitated with the highest enrichment at 0.3 kb upstream of the TSS (Figure 6b ). This enrichment was strongly reduced in dox-treated cell extracts, consistent with Spi-1 knockdown. These data indicate that Spi-1 directly binds to the Bim promoter.
Bim transcription is sensitive to epigenetic modifications of chromatin, particularly trimethylation of histone 3 on lysine 27 (H3K27me3) or DNA methylation. [28] [29] [30] [31] [32] We first evaluated DNA methylation at the Bim promoter in shSpi-1-A2C and shSpi-1-A2B cells by IP of methylated DNA (MeDIP) using an antibody against 5-methylcytidine. We detected DNA methylation at the Bim promoter between 2.1 and 1.1 kb upstream of the TSS (Figure 6c ). Then, we used bisulphite sequencing to determine accurately cytosine methylation at the Bim promoter, which includes 45 CpG dinucleotides. Comparison of the methylation profiles after the addition or not of dox showed that Spi-1 did not modify the frequency or the profile of cytosine methylation (Supplementary Figure 3) . Thus, the modulation of Bim transcription by Spi-1 was not due to a change in DNA methylation.
Next, we evaluated the trimethylation on lysine 9 (H3K9me3) or H3K27me3 by ChIP using appropriate antibodies. We did not detect any peak of H3K9me3 enrichment at the Bim promoter (Figure 6c ). Conversely, we observed H3K27me3 along the Bim promoter, with the highest enrichment 1.5 kb upstream of the TSS (Figure 6c) . Furthermore, H3K27me3 was significantly reduced in doxtreated cells compared with untreated cells, particularly in the region from 2.1 to 1.1 kb upstream of the Bim TSS (Figure 6d ). Spi-1 represses Bim transcription through functional interference with the PRC2. Then, we speculated that Spi-1 might repress Bim expression by contributing to the deposition of repressive histone marks on the Bim promoter. To check this hypothesis, we generated constructs in which a luciferase cDNA was inserted downstream of the 0.8 kb Bim promoter region that included the Spi-1 DNA binding motif (Bim0.8wt), or the 3.5 kb region that further includes the H3K27me3 sites (Bim3.5wt) (Figure 7a ). We also produced two constructs in which the Spi-1 DNA binding site was mutated (Bim0.8mut and Bim3.5mut). The mutation abolished Spi-1 binding to DNA in the EMSA assay (Supplementary Figure 4) , confirming that Spi-1 binds directly to this DNA motif. We stably transfected shSpi-A2B cells with the luciferase constructs and pools of cells were selected to analyse the promoter activity in a chromatin context. The luciferase expression was driven similarly by Bim0.8wt and Bim0.8mut promoters (Figure 7b ). In contrast, when luciferase transcription was driven by Bim3.5 promoter, mutation of the Spi-1 binding site increased luciferase expression (twofold). These results demonstrate that Spi-1 binding to the Bim promoter is necessary but not sufficient to repress Bim transcription in preleukaemic cells. The transcriptional repression of Bim requires also the repressive H3K27me3 marks. This prompted us to investigate whether H3K27me3 contributes to Bim repression in preleukaemic cells. As PRC2 is a major regulator of H3K27me3, we asked whether inhibition of PRC2 activity affected Bim transcription. To this aim, we reduced the expression of SUZ12 or EZH2, 33 two PRC2 subunits, using shRNA against Ezh2 or Suz12 or shSbl in shSpi-1-A2C cells. Suz12 or Ezh2 silencing reduced H3K27me3 (Figure 7c ). Moreover, ChIP experiments using anti-H3K27me3 antibodies indicated that H3K27me3 at the Bim promoter was significantly reduced when SUZ12 or EZH2 was depleted (Supplementary Figure 5) . In parallel, the levels of Bim transcript and BIM protein were increased in cells in which Suz12 or Ezh2 was silenced (Figure 7c ). These data demonstrate that PRC2 contributes to the deposition of the H3K27me3 mark on the Bim promoter, causing the repression of Bim transcription in preleukaemic cells.
We then asked whether Spi-1 facilitates the enrichment of H3K27me3 at the Bim promoter by recruiting and/or modulating the activity of PRC2 at the Bim promoter. Co-IP assays using shSpi-1-A2B and shSpi-1-A2C cell lysates and the anti-Spi-1 antibody indicated that EZH2 and SUZ12 interact with Spi-1 (Figure 7d ). We then examined whether EZH2 and SUZ12 bound to the Bim promoter by ChIP using appropriate antibodies. We detected EZH2 and SUZ12 at the Bim promoter at the same location as the H3K27me3 marks, with the highest enrichment at À 1.5 kb from the TSS (Figure 7e ). Conversely, we never found any EZH2 or SUZ12 bound to the Spi-1 binding site (0.3 kb downstream of 
α-SUZ12
Bim epigenetic silencing by Spi-1/PU.1 in leukaemia M Ridinger-Saison et al contributing to AML development and conferring resistance to therapy. 36 In this study, we established that Spi-1 inhibits the apoptotic mitochondrial pathway through transcriptional repression of the proapoptotic factor Bim in preleukaemic cells cultured in vitro. Indeed, BIM overexpression is sufficient to kill cells and Bim knockdown protects cells from apoptosis induced by Spi-1 silencing. Similarly, we found a significant reduction of the number of apoptotic cells among primary preleukaemic cells isolated from preleukaemic mice in comparison with wt mice, which was associated with higher Spi-1 expression and lower BIM expression. Altogether, these results demonstrate the essential role of Bim downregulation in mediating Spi-1 antiapoptotic effect.
It is worth noting that the protection of apoptosis using Bim shRNA in preleukaemic cells was partial. This may be due to the residual BIM expression. However, other pro-or antiapoptotic factors might be affected by Spi-1. In particular, the expression of BCL-X L was slightly reduced, whereas the expression of tBID was slighly increased with depletion of Spi-1, two modifications that might promote cellular death.
We found that the antiapoptotic protein MCL-1 interacts with BIM in preleukaemic cells and that upon Spi-1 silencing, the more quantity of BIM neutralizes MCL-1 by physical interaction. Moreover, the increased apoptosis associated with MCL-1 depletion using shRNA indicates that MCL-1 is the main player in the survival of preleukaemic cells. Thus, the BIM-MCL-1 interaction appears critical in controlling the pool of free MCL-1 that will determine whether a preleukaemic cell will survive or die. The free pool of MCL-1 in a low BIM context might inhibit apoptosis by neutralizing other proapoptotic factors such as BAX/BAK, tBID and PUMA that are expressed in preleukaemic cells and are capable to interact with MCL-1.
37
BIM expression is regulated at the transcriptional and translational level in many cell types. The EPO signalling pathway through ERK-mediated phosphorylation of BIM induces its proteasomal degradation in erythroid cells. 38, 39 However, we previously established that EPO signalling was not involved in the antiapoptotic function of Spi-1 in preleukaemic cells. Moreover, BIM phosphorylation and stability were not changed following Spi-1 silencing in preleukaemic cells (data not shown) that is inconsistent with a role of Spi-1 in BIM degradation. Moreover, Bim is a target of the miR-17-92 and miR106b-25 clusters 40 and Spi-1 was reported to modify the expression of the pri-miR-17-92. 41, 42 We found that the expression of the pri-miR-17-92 and pri-miR-106b-25 in preleukaemic cells was not affected by Spi-1 (data not shown), leading to exclude a role of these miRNAs in Bim repression by Spi-1 in preleukaemic cells.
We show here that transcriptional repression of Bim is the main mechanism mediated by Spi-1 to maintain BIM expression to a low level in preleukaemic cells. We demonstrate that Bim is a direct Spi-1 transcriptional target through DNA binding and transactivation assays. The occupancy of the Bim promoter by Spi-1 in macrophages was previously reported but not functionally examined. 43 It would be interesting to know whether Bim is a Spi-1 target gene in haematopoietic lineages wherein Spi-1/PU.1 behaves as a master differentiation regulator.
Studying epigenetic components of transcriptional regulation provides important clues for understanding Spi-1 function in repressing Bim transcription. Spi-1 silencing has no impact on the repressive DNA methylation of the Bim promoter, but provokes an enrichment in the repressive H3K27me3 mark at the Bim promoter. Moreover, the transcriptional repression of Bim requires Spi-1 binding to the Bim promoter and also the region containing the repressive H3K27me3 marks further upstream of the Spi-1 binding site. Finally, we identify PRC2 as a regulator of Bim expression by Spi-1 through promoting the H3K27me3 transcriptional repressive mark.
Other studies reported that Spi-1 represses gene transcription by epigenetic mechanisms involving the formation of repressive H3K9 trimethylation 44 and the recruitment of histone deacetylases. 45 Recent data also identified Spi-1 binding to enhancers as a primary event that facilitates H3K4me1 deposition. 43 Our work reveals a new mechanism whereby Spi-1 represses gene transcription, by promoting H3K27me3 deposition at chromatin.
It is still not well understood how PRCs are targeted to specific genes in mammals. As PRCs do not contain inherent specific DNA-binding activity, additional factors must mediate their chromatin recruitment, such as JARID2, non-coding RNAs and transcriptional regulators. 29, 33, 46, 47 Recruitment of PRC2 by GATA-1 has been reported during normal erythroid differentiation. 37 Abnormal recruitment of PRCs by the participates in leukaemic transformation. PRC2 might also associate with CG-rich sequences in genes devoid of DNA motifs for transcriptional activators in ES cells. 50 We found that SUZ12 and EZH2 interact with Spi-1 and bind to the Bim promoter at the H3K27me3 sites that are 0.9 kb distant from the Spi-1 binding motif. As both Spi-1 and PRC2 are required to favour H3K27m3 at the Bim promoter, at least, two scenarios might fit with these findings (Figure 7f ). In the first one, Spi-1 is not responsible for PRC2 recruitment. Spi-1 interaction with PRC2 would strengthen PRC2 activity or maintain PRC2 at the Bim promoter. The second scenario is based on the hypothesis that Spi-1 recruits PRC2 to the chromatin and that this indirect binding of PRC2 would not be detectable because of the structure of the chromatin or to the weakness of the indirect PRC2 binding to Spi-1 binding site. In both hypothesis, the PRC2 activity on histone 3 may involve intermediates, such as proteins or non-coding RNAs that may target PRC2 to the À 2.1 to À 1.1 kb region on DNA. As noncoding RNAs interact with PRC2 at repressed genes 51, 52 and because Spi-1 binds to RNA, 53 it is tempting to speculate that Spi-1 may affect PRC2 repressive activity or maintain PRC2 at the Bim promoter through its RNA-binding activity. In conclusion, our results provide evidence that a transcription factor can modulate the activity of PRC2 and epigenetic regulation without recruiting PRC2 at the site of its activity on the chromatin. Further studies are needed to determine the precise mechanism of the functional cooperation between PRC2 and Spi-1.
Genetic alterations of members of the polycomb gene (PcG) complex that confer increased or reduced activity can promote leukaemic transformation. 54, 55 We describe here the repressive consequence of PRC2 activation at the Bim promoter and associate this molecular deregulation with a functional impact on apoptosis resistance in preleukaemic erythroid progenitor cells. This illustrates how deregulation of the epigenetic activity of PcG by an oncogenic transcription factor can lead to aberrant gene silencing. It will be essential in the future to define whether this Spi-1 activity extends to other target genes that may influence Spi-1 oncogenic function as well.
Materials and Methods
Cell lines, clonogenic assays, pharmacological inhibitors and antibodies. Spi-1 transgenic cells were derived from Spi-1 transgenic mice with erythroleukaemia as described previously. 6 Cells were grown in a-MEM supplemented with 5% foetal bovine serum (FBS) and 1 U/ml EPO. Cells producing anti-Spi-1 shRNA (ShSpi-1-A2B and ShSpi-1-A2C) in the presence of 100 ng/ml dox and control cells expressing shRNA with scrambled sequence have been described previously. 8 For colony assays with purified cells from bone marrow or spleen, 10 5 cells per ml were plated in MethoCult M3334 (StemCell Technologies, Glasgow, UK) and analysed at day 3 for CFU-E.
Cells were treated with STS (10 mM) for 2 or 4 h (Calbiochem, Nottingham, UK). Actinomycin D (Sigma-Aldrich, Saint Quentin, France) were added in the culture medium at the indicated concentrations. Antibodies used in this study are listed in Supplementary Table 1 .
Cell viability, apoptosis assay and flow cytometry. For measurement of viability and apoptosis, cells were seeded at 5 Â 10 4 cells per ml in liquid medium with or without dox. Cell viability was measured by using the Trypan blue exclusion test with a Vi-Cell analyser (Beckman Coulter, Roissy, France) or by flow cytometry analysis after staining with DAPI (4 0 ,6 0 -diamidino-2-phenylindole) (Invitrogen, Saint Aubin, France).
Apoptosis was monitored with three different methods based on flow cytometry. Cells were stained with Annexin V-APC (BD Biosciences, Le Pont de Claye, France) and DAPI according to the manufacturer's instructions. Annexin V-positive cells were defined as apoptotic among the living cells (DAPI-negative). Detection of the active form of caspase-3 (cleaved-caspase-3) was performed as described previously. 9 To determine the loss of mitochondrial transmembrane potential, cells were incubated with 20 nM of 3,3 0 -Dihexyloxacarbocyanine iodide (DiOC 6 (3); Invitrogen) at 37 1C for 30 min.
Flow cytometry analyses were conducted on an LSR II flow cytometer (BD Biosciences) with the DIVA software (Beckton Dickinson). Data were analysed using the the FlowJo 9.5 software (Tree Star, Ashland, OR, USA).
In vivo staining. Bone marrow cells were flushed from femurs and washed in cold phosphate-buffered saline with 0.5% bovine serum albumin (PBS/0.5% BSA). Freshly isolated bone marrow or spleen cells were immunostained at 4 1C in PBS/ 0.5% BSA with APC-conjugated anti-Ter119 (1:100; eBioscience, Paris, France), FITC-conjugated anti-CD71 (1:100; BD Biosciences) and biotin-conjugated anti-IL3R (1:200; BD Biosciences) antibodies for 20 min, followed by a 15-min incubation with PE-conjugated streptavidin (1:1000; BD Biosciences). DAPI was used to exclude dead cells. For apoptosis measurement, stained cells using the fluorescent antibodies were incubated for additional 15 min with APCconjugated Annexin V and DAPI according to the manufacturer's instructions (BD Biosciences).
Cell sorting was performed on a FACSAria instrument (BD Biosciences) using the medium speed sorting settings with a 85 mm nozzle. Analysis of Ter119, CD71 and Annexin V labelling was carried out on an LSR II flow cytometer (BD Biosciences) with the DIVA software (Beckton Dickinson). Data were analysed using the FlowJo 9.5 software (Tree Star).
Transfection and lentiviral transduction. Cells were transfected using Amaxa Nucleofector (Lonza, Levallois Perret, France) as described previously. 8 pLKO.1-Puro vectors transducing shRNA against Bim, Mcl-1, Suz12 or Ezh2 or control shSbl were selected from the MISSION shRNA lentivirus library (SigmaAldrich). Lentiviral particles were generated as described earlier. 9 Preleukaemic cells were transduced with freshly prepared lentiviral particles and 30 h after infection 1 mg/ml puromycin (CAYLA, Toulouse, France) was added to the cells for selection. Selected cells were used for experiments 2.5 days after puromycin addition.
Plasmid construction and luciferase assay. The Bim promoter regions (0.8 or 3.5 kb) were PCR amplified from the mouse Bim promoter plasmid (kindly provided by Dr. Bouillet 18 ) and subcloned into the pGL4basic luciferase vector (Promega, Madison, WI, USA) to obtain the Bim0.8 kb and Bim3.5 kb vectors. The Spi-1 binding site (underlined) in the two vectors was then mutated (from 5 0 -AGTTCCGC-3 0 to 5 0 -AGATGGGC-3 0 ) using the QuikChange site-directed mutagenesis system (Stratagene, La Jolla, CA, USA), according to the manufacturer's recommendations. The following mutagenic oligonucleotides were used for PCR: primer forward, 5 0 -CTGAGCGCCCCCTAAGATGGGCTC TGCGAGGTGGCC and reverse, 5 0 -GGCCACCTCGCAGAGCCCATCTTAGGG GGCGCTCAG. shSpi-A2B cells were then stably transfected with the luciferase plasmids and selected with puromycin. Luciferase assays were performed using exponentially growing cells 24 h after seeding and the Luciferase Assay System (Promega), according to the manufacturer's protocol. Luminescence was recorded with a Fluostar Optima microplate reader (BMG Labtech, Champigny sur Marne, France).
IP and immunobloting. For IP of BIM, MCL-1, BCL-X L and activated BAX, 2 Â 10 7 cells were lysed in CHAPS lysis buffer (10 mM HEPES pH 7.4, 150 mM NaCl and 1% CHAPS) supplemented with protease inhibitors (complete Mini EDTA-free; Roche, Mannheim Germany). For IP of Spi-1, EZH2 and SUZ12, 4 Â 10 7 cells were lysed in the following buffer: 20 mM HEPES, 2 mM MgCl 2 , 0.5% NP-40, 100 mM NaCl and 0.1% Triton. Supernatants were incubated with 2 mg of antibody and 10 ml of magnetic beads (Dynabeads; Invitrogen). Whole-cell extracts or immunoprecipitates were fractionated by SDS-PAGE and immunoblotted as described previously. 4 Images of blots were acquired using a Fujifilm LAS4000 digital imager and quantified with the Fujifilm Multi-Gauge Imaging software (Fujifilm, Tokyo, Japan).
